Table 1 Baseline demographics and disease characteristics
|  | Arm 1 MTX or SSZ monotherapy (n = 32) | Arm 2 Combo MTX+ 6 wks prednisone (n = 32) | Arm 3 Combo MTX+ etanercept (n = 30) |
|---|---|---|---|
Age (years) | 8.8 (4.8-12.7) | 10.2 (6.6-13.9) | 8.6 (4.2-12.4) |
Symptom duration* (month) | 7.8 (5.3-11.6) | 5.9 (4.4-13.3) | 8.5 (5.0-13.1) |
ANA positive (%) | 15 (47) | 11 (34) | 9 (30) |
Female (%) | 24 (75) | 19 (59) | 20 (67) |
JIA category: | Â | Â | Â |
Oligo (persistent) Poly articular Psoriatic (poly) | 5 (3) 22 5 | 3 (1) 22 7 | 2 (2) 24 4 |
VAS physician (mm) | 48 (40-55) | 50 (39-58) | 51 (37-61) |
VAS patient/parent (mm) | 48 (31-58) | 59 (35-74) | 58 (39-71) |
CHAQ (0-3) | 0.88 (0.28-1.50) | 0.94 (0.63-1.69) | 0.88 (0.75-1.53) |
No. active joints | 7.5 (5.0-12.5) | 7.5 (6.0-11.8) | 8.5 (5.8-13.0) |
No. limited joints | 2 (0-4.5) | 2 (1.0-3.8) | 3 (1.8-5.0) |
ESR (mm/hour) | 6.5 (2-11) | 6.0 (2-24) | 9.0 (4-25) |
JADAS-10 (0-40) | 15.7 (13.5-20.2) | 17.9 (15.2-21.9) | 19.1 (13.8-23.2) |